 |
| Global Niemann-Pick Disease Drug Type C Treatment Market Size |
Niemann-Pick disease types C (NPC) is a rare and fatal genetic disorder
characterized by abnormal accumulation of cholesterol in cells. NPC treatment
aims to alleviate neurological issues caused by the disease. Currently
available NPC drugs treat disease symptoms and slow disease progression. The
increasing R&D investments by pharmaceutical companies to develop novel
therapies for NPC is expected to drive market growth.
The global
Niemann-Pick Disease Drug Type C Treatment Market is estimated to be valued at US$ 55.39 Mn in 2023 and is expected to
exhibit a CAGR of 22% over the
forecast period 2023 to 2030, as highlighted in a new report published by
Coherent Market Insights.
Market key trends:
The increased R&D activities by prominent players in Niemann-Pick Disease
Drug Type C Treatment Market is one of the major trends being witnessed in the
market. Leading pharmaceutical companies are expanding their NPC treatment
pipelines to address the unmet needs and improve clinical outcomes. For instance,
Sarepta Therapeutics, Inc. recently initiated a phase II study to investigate
its investigational drug SRP-9001 for the treatment of NPC. Cyclo Therapeutics,
Inc. is developing Trappsol Cyclo to improve neurological involvement in NPC
patients. Significant R&D investments are expected to result in the
approval of new drugs with novel mechanisms of action, thus accelerating the
overall market growth over the forecast period.
Segment
Analysis
The global Niemann-Pick Disease Drug Type C Treatment market is segmented based
on type and end user. Based on type, the market is segmented into substrate
reduction therapy (SRT) and disease modifying treatment (DMT). Currently, the
SRT segment dominates the market due to availability of treatment options such
as miglustat which is the only approved drug globally for Niemann-Pick Disease
Type C. However, the DMT segment is expected to witness higher growth during
the forecast period owing to increasing research and development on gene and
enzyme therapies for definitive treatment of this rare genetic disorder.
Key Takeaways
The Global
Niemann-Pick Disease Drug Type C Treatment Market Size is estimated to
be valued at US$ 55.39 Mn in 2023
and is expected to exhibit a CAGR of 22%
over the forecast period 2023 to 2030.
Regional analysis: North America is expected to dominate the global market
during the forecast period owing to advanced healthcare infrastructure, rising
research and development activities backed by increasing government funding in
the region.Asia Pacific is anticipated to witness the fastest growth rate over
the forecast period owing to rising government initiatives to increase
awareness and availability of treatments in the region.
Key players: Key players operating in the Niemann-Pick Disease Drug Type C
Treatment market are Johnson & Johnson, Intrabio, Cyclo Therapeutics, Inc.,
Kempharm, Inc., Azafaros B.V., and Sarepta Therapeutics, Inc. Johnson &
Johnson dominates the market owing to its drug miglustat which is the only
approved therapy globally for type C Niemann-Pick disease. However, other
players are focusing on developing enzyme replacement therapies, gene
therapies, and substrate enhancement therapies through extensive research and
clinical trials to have novel treatment options for this rare genetic
condition.
Get More Insights On This Topic: https://www.pressreleasebulletin.com/niemann-pick-disease-drug-type-c-treatment-market-share/